128 related articles for article (PubMed ID: 8427136)
1. Long-term outcome of enoximone therapy in patients with refractory heart failure.
Dec GW; Fifer MA; Herrmann HC; Cocca-Spofford D; Semigran MJ
Am Heart J; 1993 Feb; 125(2 Pt 1):423-9. PubMed ID: 8427136
[TBL] [Abstract][Full Text] [Related]
2. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Shakar SF; Abraham WT; Gilbert EM; Robertson AD; Lowes BD; Zisman LS; Ferguson DA; Bristow MR
J Am Coll Cardiol; 1998 May; 31(6):1336-40. PubMed ID: 9581729
[TBL] [Abstract][Full Text] [Related]
3. Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents.
Simonton CA; Daly PA; Kereiakes D; Modin G; Chatterjee K
Chest; 1987 Jul; 92(1):118-23. PubMed ID: 2954776
[TBL] [Abstract][Full Text] [Related]
4. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine].
Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M
Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823
[TBL] [Abstract][Full Text] [Related]
5. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy.
Prazak P; Pfisterer M; Osswald S; Buser P; Burkart F
Eur Heart J; 1996 Feb; 17(2):251-7. PubMed ID: 8732379
[TBL] [Abstract][Full Text] [Related]
6. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Weber KT; Janicki JS; Jain MC
J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
[TBL] [Abstract][Full Text] [Related]
7. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
8. [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure].
Saborowski F; Peters P; Schneider M
Z Kardiol; 1991; 80 Suppl 4():63-7. PubMed ID: 1833900
[TBL] [Abstract][Full Text] [Related]
9. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy.
van den Broek SA; van Veldhuisen DJ; de Graeff PA; Landsman ML; Hillege H; Lie KI
Am J Cardiol; 1992 Aug; 70(3):359-63. PubMed ID: 1632403
[TBL] [Abstract][Full Text] [Related]
10. Comparative hemodynamic effects of intravenous digoxin and enoximone in severe chronic heart failure.
Casella G; Cantelli I; Pavesi PC; Barbato G; Bracchetti D
Cardiology; 1994; 85(5):303-10. PubMed ID: 7850820
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with oral enoximone for chronic congestive heart failure: the European experience.
Treese N; Erbel R; Pilcher J; Choraria S; Rhein S; Dieterich HA; Meyer J
Am J Cardiol; 1987 Aug; 60(5):85C-90C. PubMed ID: 2956876
[TBL] [Abstract][Full Text] [Related]
12. Mid-term results of heart transplantation, cardiomyoplasty, and medical treatment of refractory heart failure caused by idiopathic dilated cardiomyopathy.
Bocchi EA; Bellotti G; Moreira LF; Bacal F; de Moraes AV; Fiorelli A; Mansur A; Stolf N; Jatene A; Pileggi F
J Heart Lung Transplant; 1996 Jul; 15(7):736-45. PubMed ID: 8820791
[TBL] [Abstract][Full Text] [Related]
13. The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmias.
Miles WM; Heger JJ; Minardo JD; Klein LS; Prystowsky EN; Zipes DP
Am Heart J; 1989 Jan; 117(1):112-21. PubMed ID: 2521415
[TBL] [Abstract][Full Text] [Related]
14. Long-term enoximone therapy in unstable chronic heart failure.
Treese N; Rhein S; Erbel R; Meyer J
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S78-83. PubMed ID: 2480491
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic effects of prolonged enoximone infusion (7 days) in patients with severe chronic heart failure.
Gibelin P; Dadoun-Dybal M; Candito M; Robillon JF; Morand P
Cardiovasc Drugs Ther; 1993 Jun; 7(3):333-6. PubMed ID: 8364003
[TBL] [Abstract][Full Text] [Related]
16. [Continuous enoximone infusion in patients with severe heart failure in dilated cardiomyopathy, hemodynamic, neurohumoral, chemical laboratory and clinical results].
Neuzner J; Mitrovic V; Pitschner HF; Lissmann H; Schlepper M
Z Kardiol; 1991 Jun; 80(6):397-403. PubMed ID: 1681628
[TBL] [Abstract][Full Text] [Related]
17. Dynamic cardiomyoplasty at seven years.
Carpentier A; Chachques JC; Acar C; Relland J; Mihaileanu S; Bensasson D; Kieffer JP; Guibourt P; Tournay D; Roussin I
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):42-52; discussion 52-4. PubMed ID: 8321004
[TBL] [Abstract][Full Text] [Related]
18. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Ponikowski P; Anker SD; Chua TP; Szelemej R; Piepoli M; Adamopoulos S; Webb-Peploe K; Harrington D; Banasiak W; Wrabec K; Coats AJ
Am J Cardiol; 1997 Jun; 79(12):1645-50. PubMed ID: 9202356
[TBL] [Abstract][Full Text] [Related]
19. Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure--a subgroup analysis from the Trieste Cardiomyopathy Registry.
Aleksova A; Sabbadini G; Merlo M; Pinamonti B; Barbati G; Zecchin M; Bussani R; Silvestri F; Iorio AM; Stolfo D; Dal Ferro M; Dragos AM; Meringolo G; Pyxaras S; Lo Giudice F; Perkan A; di Lenarda A; Sinagra G
J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):699-705. PubMed ID: 19474760
[TBL] [Abstract][Full Text] [Related]
20. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.
Castelli G; Fornaro A; Ciaccheri M; Dolara A; Troiani V; Tomberli B; Olivotto I; Gensini GF
Circ Heart Fail; 2013 Sep; 6(5):913-21. PubMed ID: 23888044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
